CTOs on the Move

SutroVax

www.sutrovax.com

 
SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. SutroVax`s lead product candidate is a pneumococcal conjugate vaccine (PCV) that is designed to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. SutroVax`s broad-spectrum PCV is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. The current mainstay vaccine only covers approximately 40% of the circulating strains causing IPD yet generates $6B in annual sales. SutroVax has generated positive pre-clinical proof-of-concept ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sutrovax.com
  • 353 Hatch Drive
    Foster City, CA USA 94404
  • Phone: 650.837.0111

Executives

Name Title Contact Details

Funding

SutroVax raised $22M on 07/23/2015
SutroVax raised $64M on 03/22/2017
SutroVax raised $60M on 03/21/2017
SutroVax raised $110M on 00/00/0000

Similar Companies

ArrePath

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.

South Pacific Bio Medical

South Pacific Bio Medical is a Temecula, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tmunity

Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)

HemoShear Therapeutics

We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life.

Cara Therapeutics

Learn more about Cara Therapeutics, a biotechnology company focusing on pharmaceutical product development for better pruritus and pain management.